Mir Imran

Born and raised in Hyderabad, India, the son of a doctor, Imran was a problem-solver from a young age. As a child, he enjoyed taking toys apart to see how they worked, and as a teenager learned how to repair and build AM radios.[3]

After attending All Saints High School in Hyderabad, Imran moved to New Jersey in 1973 to attend Rutgers University.[4] At Rutgers he received a BS in electrical engineering in 1976, followed by an MS in biomedical engineering. He then spent three years At Rutgers Medical School before deciding to leave and work on the first implantable cardioverter-defibrillator with Intec Systems.

Imran attributes his pursuit of innovation to being inspired by an experience he had as a college student: “I had a summer job working at The Matheney School for Cerebral Palsy Children. They needed engineers to develop communication devices for quadriplegic cerebral palsy children, so I built a machine for one severely afflicted girl. The unit translated her facial expressions using pre-recorded phrases, allowing her to communicate.”[3]

Imran says that he is motivated by "understanding and trying to solve big problems in medicine."[3] His interest is to develop medical devices that blur the distinction between organic and synthetic and advance patient treatment.

He joined Intec Systems in 1980 and developed IP key to the development of the automatic implantable defibrillator, a device that has saved hundreds of thousands of lives, and has become a standard of care in cardiology. Intec Systems was acquired by Eli Lily, spun out to form Guidant, and acquired by Boston Scientific in 2006 for $27.5 billion.

In 1992, Imran invented a cooled RF ablation catheter for the treatment of ventricular arrhythmias. This invention became the initial product of Cardiac Pathways, and is now widely used by cardiac electro-physiologists.

In 1995, he developed a low-pressure balloon and aspirator system for use in catheter-based interventions. Imran was the first to articulate the concept of embolic protection during high-risk interventions, and his device became the primary innovation for Percusurge, which was acquired by Medtronic in December 2000.

In 2017, Imran announced the development of the Rani pill, a novel approach to the oral delivery of large drug molecules which previously have only been deliverable via injections.[3][5] Imran describes this development as “a mini swallowable auto-injector” that delivers the drug directly into the highly vascular intestine wall, allowing the drug to be absorbed quickly into the bloodstream.[1][3]

Imran’s research interests are wide-ranging and include tissue engineering, gastroenterology, nephrology, neurology, orthopedics, congestive heart failure and artificial organs.[4]

Imran is an active angel investor and a limited partner in several venture funds. He is the founder and Managing Director of InCube Ventures, a medical device venture fund.

2005: Rutgers University Distinguished Engineer Award[7]

2009: Rutgers Hall of Distinguished Alumni

2010: Neurotech Reports’ Gold Electrode Award for Most Valuable Financial Professional

2015: Fellow of the National Academy of Inventors (US)

2017: Admitted to the National Academy of Engineering (US)

2018: Named as one of the San Francisco Business Time and Silicon Valley Business Journal’s Upstart 50[8]

2018: MedTech Innovation Catalyst Award, for outstanding and life-saving innovations in the medical field[9]

• InCube Labs
• InCube Ventures
• eeTimes Magazine – 7 November 2005 – featuring Mir Imran
• Healthy Entrepreneurship in Medical Devices, podcast of Mir Imran speaking at Stanford
• Stanford Medicine, Fall 2006 – Device Guru’s article featuring Mir Imran
• UT Dallas, Engineering in Medicine and Biology – 12 November 2007 – Keynote presentation by Mir Imran.
• Patents with Mir Imran listed as Inventor – USPTO.gov
• InCube Labs in the Daily Telegraph, UK